Table 2. Effect of nucleoside and non-nucleoside ligands on normal and tumor human cell lines.
S.No | Ligand | Number of viable cells after 24/48 h of ligand treatment | ||||||
CRL-2115 | CRL-2120 | NCM-460 | He La | MCF-7 | B16F10 | A549 | ||
1. | L1 | +/++ | +/++ | +/++ | +/++ | +/++ | ++/+++ | +/++ |
2. | L2 | +/++ | +/++ | +/++ | +/++ | +/++ | ++/+++ | ++/++ |
3. | L3 | +/++ | +/++ | +/++ | ++/++ | ++/++ | ++/+++ | ++/+++ |
4. | L4 | +/++ | +/+ | +/++ | +/++ | ++/++ | ++/++ | +/++ |
5. | L5 | +/++ | +/++ | +/++ | ++/++ | ++/++ | ++/++ | +/++ |
6. | L6 | +/++ | +/++ | ++/++ | ++/++ | +/++ | +/++ | ++/++ |
7. | L7 | +/+ | +/++ | +/++ | +/+ | +/++ | +/++ | +/+ |
8. | L8 | +/+ | +/+ | +/++ | +/++ | +/+ | +/++ | +/++ |
9. | L9 | +/++ | +/+ | +/+ | +/++ | +/+ | +/++ | +/++ |
10. | L10 | +/+ | +/+ | +/++ | +/+ | +/++ | +/++ | +/+ |
11. | L11 | +/+ | +/+ | +/+ | +/++ | +/++ | +/++ | +/++ |
12. | L12 | +/+ | +/+ | +/++ | +/++ | +/++ | +/++ | +/+ |
13. | L13 | +/+ | +/+ | +/+ | +/++ | +/+ | +/++ | +/+ |
14. | L14 | +/+ | +/+ | +/++ | +/+ | +/++ | +/++ | +/++ |
+ - Viable cells in the range of 80%–90% ; ++ - Viable cells in the range of 50%–60% ; +++ - Viable cells which are equal or less than 30%.